Antiviral Therapies and Treatment Strategies

Managing chronic Hepatitis B is a marathon, not a sprint. The primary goal of modern therapy is to protect your liver by keeping the virus under control ^[1]. While we cannot yet “delete” the virus from the body entirely, we have powerful tools to suppress it so effectively that your liver can stay healthy for a lifetime ^[2][3].

When to Start Treatment

Deciding when to start treatment is a specialized process based on international guidelines from organizations like the AASLD and EASL ^[4]. Doctors generally do not treat the virus just because it is there. Instead, they look for proof that the virus is actively causing harm. The decision is usually based on a combination of three factors:

1. HBV DNA (Viral Load): An elevated viral load (often >2,000 IU/mL) is a prerequisite for treatment, but it is rarely enough on its own ^[5].
2. ALT Levels: The elevated viral load must usually be accompanied by elevated ALT liver enzymes, which proves that the immune system is actively attacking the liver and causing inflammation ^[4].
3. Liver Scarring (Fibrosis): If a FibroScan or biopsy shows significant scarring (moderate fibrosis or cirrhosis), treatment is usually started immediately to prevent further damage, regardless of ALT levels ^[5][6].

The “Watch and Wait” Phases

Not everyone needs medication immediately. You may fall into a phase where monitoring (usually every 3 to 6 months) is the standard of care:

• Immune-Tolerant Phase: The viral load is very high, but the immune system is ignoring it. ALT levels are normal and there is no liver scarring ^[4]. The risk of liver damage is very low right now, though some newer research suggests early treatment may benefit select patients ^[7].
• Inactive Carrier Phase: The immune system has successfully suppressed the virus. The viral load is very low or undetectable, ALT is normal, and the HBeAg marker is negative.

The Standard of Care Medications

If you need treatment, there are two main approaches: Daily pills or a finite course of injections.

Oral Pills: Nucleos(t)ide Analogues (NAs)

These daily pills block the virus’s ability to copy itself. They are the most common treatment.

• Entecavir (ETV): A highly effective, well-tolerated pill with a very low risk of the virus developing resistance to it ^[8].
• Tenofovir Disoproxil Fumarate (TDF): A potent antiviral that is extremely effective at suppressing the virus ^[9]. However, because it can sometimes affect the kidneys or bone density over many years, it may not be the first choice for older adults or those with pre-existing bone or kidney issues ^[8].
• Tenofovir Alafenamide (TAF): A newer version of tenofovir designed to deliver the medicine more directly to the liver cells, allowing for a much lower dose ^[10]. This makes it safer for the kidneys and bones than TDF while maintaining the same viral-fighting power ^[11].

Injections: Pegylated Interferon (Peg-IFN)

Unlike oral pills which are usually taken long-term, Peg-IFN is a weekly injection given for a finite period (usually 48 weeks). It works by boosting the body’s immune system to fight the virus. While it offers the chance of stopping treatment after a year, it often comes with more significant side effects (like flu-like symptoms and fatigue) and is only suitable for specific patient profiles.

Defining the “Cure”

In Hepatitis B, we talk about two types of “cure,” though it is important to manage expectations regarding current medications:

• Functional Cure: This occurs when the HBsAg (surface antigen) completely disappears from your blood ^[12]. This is a major clinical goal because it drastically reduces the risk of liver cancer and may allow you to stop medication. However, losing HBsAg while taking current oral NAs (like ETV, TDF, or TAF) is very rare (only about 1-3% of patients achieve this). For the vast majority of patients, NA therapy is a long-term, often lifelong, daily commitment to keep the virus suppressed ^[13].
• Complete (Sterilizing) Cure: This would mean removing every trace of the virus, including the cccDNA hiding in the liver cells ^[14]. Current medications cannot do this because they do not destroy the genetic “blueprints” in the cell nucleus ^[2].

Research into new drugs designed to achieve a complete cure is advancing rapidly. For now, the focus is on maintaining excellent health through consistent daily medication and routine monitoring ^[15].